Back to

Jorge Santos da Silva

Partner, Zurich
Counsels biopharmaceutical, medical device, and diagnostic companies in mature and emerging markets on strategy, operating models, and organization

About Jorge

Jorge is a leader in our Pharmaceutical & Medical Products Practice. He advises biopharma, medical device, and diagnostic companies on corporate and business-unit strategy, commercial operating models, R&D, organizational design, M&A, joint ventures, and marketing and sales.

In the past few years, Jorge has:

  • worked with several companies to define strategies for biopharma products at a global level and in specific emerging markets, including implementation and business plans.
  • helped a top generics company to design its operating models in emerging markets, including country-by-country scenario development, portfolio management, and M&A screening.
  • supported the formation of biopharma joint ventures and public–private partnerships in emerging markets.
  • developed growth options for a medical diagnostics company, including local technology platforms.
  • led our support for major integrations and commercial transformations across geographic regions and product ranges.
  • performed due diligence on biopharma companies, with emphasis on the biotech process and portfolio.

Jorge has published a number of articles on pharma R&D, biosimilars, and other industry topics, as well as several scientific papers written during his earlier research career. With an academic background in molecular biology and neuroscience, he holds a BSc from the University of Glasgow, an MSc from EMBL in Heidelbert, and a PhD from the University of Turin. He completed his post-doctoral studies at the Cold Spring Harbor Laboratory in New York.

Published work

What’s ahead for biotech: Another wave or low tide?,” McKinsey & Company, April 2021

Understanding the opportunity in Japan’s biosimilar market,” McKinsey & Company, September 2019

“Biotech in Europe: A strong foundation for growth and innovation,” McKinsey & Company, August 2019

What’s next for biosimilars in emerging markets?,” McKinsey & Company, April 2019

Five things to know about biosimilars right now,” McKinsey & Company, July 2018

Africa: A continent of opportunity for pharma and patients,” McKinsey & Company, June 2015

“The rise of biosimilars: Navigating the distinctive path to market,” From Science to Operations: Questions, choices, and strategies for success in biopharma (PDF–790 KB), McKinsey & Company, 2014

Biosimilars seven years on: Where are we and what's next?,” McKinsey & Company, February 2013 (PDF–657 KB)

“Public–private partnerships: An untapped strategic lever,” Unlocking pharma growth (PDF–2.91 MB), McKinsey & Company, 2012

Closing the R&D gap in African health care,” Evolution or revolution?, McKinsey & Company, 2012

Past experience

Cold Spring Harbor Laboratory, New York


University of Turin
PhD, neuroscience

European Molecular Biology Laboratory, Heidelbert
MSc, neurobiology

University of Glasgow
BSc, molecular biology